Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
88, nos
CJC-1295 (No DAC) + Ipamorelin also written CJC 1295 or CJC1295 is a dual-peptide research formulation that pairs a short-acting GHRH analogue (CJC-1295 No DAC) with a selective growth-hormone-releasing peptide (Ipamorelin, a ghrelin/GHS-receptor agonist)
Retatrutide Retatrutide represents another approach to multi-pathway activation, functioning as a triple agonist (GIP/GLP-1/glucagon) in a single molecule: Cagrilintide + GLP-1 Approach: Two separate injections Amylin + GLP-1 pathways Established safety profile for each component Flexible dose adjustment of each component Retatrutide Approach: Single injection GIP + GLP-1 + Glucagon pathways Novel triple mechanism in one molecule Fixed ratio of pathway activation Both approaches show promise for significant metabolic benefits, though they achieve multi-pathway activation through different strategies
Preclinical research indicates GHK-Cu may extend this phase, but equivalent human evidence is lacking
R&D Systems recommends, if flakes persist, to mix the solution for a couple of hours at room temp and then at 4C overnight1
Injectable forms generally offer stronger and more predictable results, while nasal sprays provide a simpler and more approachable option for patients prioritizing ease of use
US$ 22.69
US$ 20.31
US$ 26.52
US$ 29.65
US$ 21.50
US$ 27.61
